

REMARKS

In the Office action of October 30, 2008, the Examiner rejected claims 1-6, 11 and 12 for lack of written description, to the extent that the claims related to proteins other than PhoS/PstS. Claims 7-10 were objected as depending from a rejected base claim. Accordingly, all prior claims 1-12 have been cancelled and a new set of claims 13-21 is entered herein, the new claims relating solely to the PhoS/PstS protein.

Claim 13 is directed to an *E.coli* host cell expressing a recombinant antibody in which the isoelectric point of the Phosphate binding protein (PhoS) of the host cell has been altered by the addition of an amino acid tag to the C-terminus and/or by changing one or more of the residues located on the surface of the *E.coli* PhoS protein. Basis for this claim can be found in claims 1, 3 and 5 of the application as filed and on page 5 lines 2-7 and page 9 line 13.

Claim 14 specifies that the amino acid tag of claim 1 is a poly-aspartic acid tag. Basis for this claim is found in claim 6 of the application as filed.

Claim 15 specifies that the surface residues changed in claim 13 are lysine and/or arginine residues and that these are substituted for aspartic acid or glutamic acid residues or vice versa. Basis for this claim can be found in the application as filed on page 10, lines 20-25.

Amended Claims 16 to 21 correspond to claims 7-12 of the application as filed.

Applicants submit that the newly submitted claims 13-21 are in condition for allowance. Should the Examiner feel that further dialog would advance the subject application to issuance, the Examiner is invited to telephone the undersigned at (312) 913-0001.

Please charge any necessary fees to Deposit Account No. 13-2490.

Respectfully submitted,

Date: March 30, 2009

By: /Sandra B. Weiss/

Sandra B. Weiss
Reg. No. 30,814
McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-3362